Isobutane

Isobutane

SCHEMBL1229517

CC(C)C.CCC(=N)N.Cl

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Isobutane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SPHK2 Q9NRA0 1/20 0.38
SPHK1 Q9NYA1 1/20 0.38
NOS3 P29474 5/20 0.36
NOS1 P29475 5/20 0.36
NOS2 P35228 5/20 0.36
TSHR P16473 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
BLM P54132 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 1/20 0.30
IDO1 P14902 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28067391 0.89 SPHK2 (0.43) SPHK2SPHK1NOS3NOS1NOS2
Hydrochloric Acid SCHEMBL166054 0.89
Hydrochloric Acid SCHEMBL2689253 0.89
SCHEMBL20985100 0.87 SPHK2 (0.38) SPHK2SPHK1NOS3NOS1NOS2
SCHEMBL12181 0.86
Iodide SCHEMBL30575029 0.82
Hydrazine SCHEMBL10430760 0.82
Water SCHEMBL30816099 0.82
SCHEMBL21351628 0.73
Bicarbonate SCHEMBL6620515 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459607-B1 HYBRID COPOLYMER COMPOSITIONS FOR PERSONAL CARE APPLICATIONS NOURYON CHEMICALS INT BV (NL) 2021-04-14 EP disclosed
EP-2459606-B1 HYBRID COPOLYMER COMPOSITIONS NOURYON CHEMICALS INT BV (NL) 2020-10-21 EP disclosed
US-9988526-B2 Hybrid dendrite copolymers, compositions thereof and methods for producing the same AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) 2018-06-05 US disclosed
US-9321873-B2 Hybrid copolymer compositions for personal care applications AKZO NOBEL N.V. (NL) 2016-04-26 US disclosed
EP-2773320-B1 HYBRID DENDRITE COPOLYMERS, COMPOSITIONS THEREOF AND METHODS FOR PRODUCING THE SAME AKZO NOBEL CHEMICALS INT BV (NL) 2016-02-03 EP disclosed
US-9109068-B2 Hybrid copolymer compositions AKZO NOBEL N.V. (NL) 2015-08-18 US disclosed
US-20140256880-A1 Hybrid dendrite copolymers, compositions thereof and methods for producing the same NOURYON CHEMICALS INTERNATIONAL B.V. (NL) 2014-09-11 US disclosed
EP-2773320-A1 HYBRID DENDRITE COPOLYMERS, COMPOSITIONS THEREOF AND METHODS FOR PRODUCING THE SAME Akzo Nobel Chemicals International B.V. (NL) 2014-09-10 EP disclosed
US-20130292611-A1 HYBRID MIXTURES FOR GAS HYDRATE INHIBITION APPLICATIONS AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) 2013-11-07 US disclosed
EP-2658945-A1 HYBRID MIXTURES FOR GAS HYDRATE INHIBITION APPLICATIONS Akzo Nobel Chemicals International B.V. (NL) 2013-11-06 EP disclosed
WO-2013064647-A1 HYBRID DENDRITE COPOLYMERS, COMPOSITIONS THEREOF AND METHODS FOR PRODUCING THE SAME AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) 2013-05-10 WO disclosed
WO-2012089654-A1 HYBRID MIXTURES FOR GAS HYDRATE INHIBITION APPLICATIONS AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) 2012-07-05 WO disclosed
EP-2459606-A1 HYBRID COPOLYMER COMPOSITIONS Akzo Nobel N.V. (NL) 2012-06-06 EP disclosed
EP-2459607-A1 HYBRID COPOLYMER COMPOSITIONS FOR PERSONAL CARE APPLICATIONS Akzo Nobel N.V. (NL) 2012-06-06 EP disclosed
US-20120134942-A1 Hybrid copolymer compositions for personal care applications AKZO NOBEL N.V. (NL) 2012-05-31 US disclosed
US-20120128608-A1 Hybrid copolymer compositions AKZO NOBEL N.V. (NL) 2012-05-24 US disclosed
WO-2011017223-A1 HYBRID COPOLYMER COMPOSITIONS FOR PERSONAL CARE APPLICATIONS AKZO NOBEL N.V. (NL) 2011-02-10 WO disclosed
WO-2011014783-A1 HYBRID COPOLYMER COMPOSITIONS AKZO NOBEL N.V. (NL) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120128608-A1 Hybrid copolymer compositions EPHX2, PUF60, ELOVL6 SPHK2 3833/4885SPHK1 4143/4885NOS3 2029/4885
US-20120134942-A1 Hybrid copolymer compositions for personal care applications CUTA, MMS19, POLH SPHK2 3046/4885SPHK1 3258/4885NOS3 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.